Immunoassay MarketSize, Share & Industry Analysis, 2026-2034By ProductBy SpecimenBy TechnologyBy ApplicationBy End-use
Full title & scope — all 5 axes with their segments
Immunoassay Market Size, Share & Industry Analysis, By Product (Reagents & Kits, ELISA Reagents & Kits, Rapid Test Reagents & Kits, ELISPOT Reagents & Kits, Western Blot Reagents & Kits, Other Reagents & Kits, Open Ended Systems, Closed Ended Systems, Software & Services), By Specimen (Blood, Urine, Saliva, Other Specimens), By Technology (Radioimmunoassay, Enzyme Immunoassays (EIA)Rapid Test, Chemiluminescence Immunoassays, Fluorescence Immunoassays, Others), By Application (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease Testing, Autoimmune Diseases, Others), By End-use (Hospitals, Blood Banks, Clinical Laboratories, Pharmaceutical and Biotech Companies, Academic Research Centers, Others), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By ProductReagents & Kits · ELISA Reagents & Kits · Rapid Test Reagents & Kits
- 02By SpecimenBlood · Urine · Saliva
- 03By TechnologyRadioimmunoassay · Enzyme Immunoassays · Chemiluminescence Immunoassays
- 04By ApplicationTherapeutic Drug Monitoring · Oncology · Cardiology
- 05By End-useHospitals · Blood Banks · Clinical Laboratories
- 06By Region
Market Analysis & Outlook
Immunoassays are laboratory and point-of-care tests that detect and measure a target antigen or antibody using labeled reagents, typically run on automated analyzers or as single-use cartridges and kits. The category spans reagents, instruments and increasingly software that connects a laboratory's device fleet, taking forms ranging from bench-top chemiluminescence analyzers in hospital laboratories to lateral-flow rapid tests used at the point of care. Buyers include hospital and reference laboratories, blood banks, pharmaceutical and biotech companies running clinical trial assays, and academic research centers.
The global immunoassay market stood at USD 33.5 billion in 2025. A forecast-period rate of 6.82% takes it to USD 60.95 billion by 2034, and the study reports every year in between, passing USD 22.8 billion in 2020, USD 31 billion in 2024, USD 35.95 billion in 2026 and USD 47.25 billion in 2030.
On the product axis, growth rates run from 5.23% for ELISA Reagents & Kits up to 9.2% for Software & Services. ELISA Reagents & Kits carries the volume: USD 8.04 billion and 24% of revenue in 2025, USD 12.8 billion and 21% in 2034. Rapid Test Reagents & Kits, ELISPOT Reagents & Kits, Closed Ended Systems and Software & Services take share over the period; Reagents & Kits, ELISA Reagents & Kits, Western Blot Reagents & Kits, Other Reagents & Kits and Open Ended Systems give it up while still growing in absolute terms.
The specimen split puts Blood first, at USD 22.78 billion and 68% of revenue in 2025, rising to USD 39.62 billion and 65% in 2034. Saliva grows faster at 10.35% against 6.34%, moving from 9% of revenue to 12% by 2034. It cuts the same total as the product axis from a different commercial angle, so revenue does not add across the two.
USD 12.08 billion of 2025 revenue is generated in North America, 36.1% of the global total and the largest regional share; it reaches USD 20.42 billion by 2034. Europe is next at 26.1% and USD 8.75 billion, and Middle East and Africa last at 5.9%. Because Asia Pacific and Latin America take share, the revenue added by 2034 concentrates rather than spreading across all five regions.
Behind these figures sit five regions, nine product lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is triangulated from published sources and category proxies rather than an independently sourced count, and the same applies to the segment, regional and country breakdowns drawn from it.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- Revenue grows from USD 33.5 billion in 2025 to USD 60.95 billion in 2034, a compound annual rate of 6.82%, having reached USD 31 billion in 2024 from USD 22.8 billion in 2020.
- ELISA Reagents & Kits is the largest product line at USD 8.04 billion in 2025, a 24% share, reaching USD 12.8 billion and 21% of revenue by 2034.
- Fastest growth on the product axis belongs to Software & Services: 9.2% a year, USD 3.02 billion to USD 6.71 billion, and a share moving from 9% to 11%.
- Against a base case of USD 60.95 billion in 2034, the study also reports a bear case at USD 57.29 billion and a bull case at USD 64.61 billion, with the assumptions behind each set out separately.
- 36.1% of 2025 revenue is generated in North America, worth USD 12.08 billion and rising to USD 20.42 billion by 2034; Middle East and Africa is smallest at 5.9%.
- 86.09% of North America's base-year revenue comes from the United States alone: USD 10.4 billion in 2025, rising to USD 17.55 billion by 2034, which is why it is that region's worked example.
- Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region rather than a single blended series.
Market Trends
Revenue Share, By by product
Base year 2025ELISA Reagents & Kits leads with 24.0% of by product segment revenue.
Share of by product segment revenue, most recent base year. The 3 smallest segments are grouped as Other.
Three movements define the forecast period in the global immunoassay market: how the product mix changes, where regional weight shifts, and the rate at which the total compounds.
None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.
Software & Services outpaces ELISA Reagents & Kits. 9.2% against 5.23%: that gap, between Software & Services and ELISA Reagents & Kits, is the largest on the product axis. Over the forecast period that moves Software & Services from 9% of revenue to 11%, and ELISA Reagents & Kits from 24% to 21%. Neither contracts: USD 3.02 billion becomes USD 6.71 billion, USD 8.04 billion becomes USD 12.8 billion. What the spread decides is which of them a supplier's revenue is exposed to.
Growth concentrates in Asia Pacific and Latin America. Asia Pacific moves from 25.3% of revenue in 2025 to 29.5% in 2034, worth USD 8.48 billion rising to USD 17.98 billion; Latin America moves from 6.6% of revenue in 2025 to 6.8% in 2034, worth USD 2.21 billion rising to USD 4.15 billion. The offsetting side is North America at 36.1% moving to 33.5%, Europe at 26.1% moving to 24.5%, Middle East and Africa at 5.9% moving to 5.7%, none of which contracts. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.
The series never breaks trajectory. Year by year the total runs USD 22.8 billion in 2020, USD 31 billion in 2024, USD 33.5 billion in 2025, USD 35.95 billion in 2026, USD 47.25 billion in 2030 and USD 60.95 billion in 2034. The forecast rate of 6.82% sits against 8% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the product and regional axes, not by the headline rate.
Market Growth Factors
Software & Services adds the most incremental growth
Market Drivers
3- 01Software & Services adds the most incremental growth
Software & Services compounds at 9.2% against 6.82% for the market, rising from USD 3.02 billion in 2025 to USD 6.71 billion in 2034 and from 9% of revenue to 11%. Nothing else on the axis grows as fast (ELISA Reagents & Kits manages 5.23%) so the blended 6.82% is carried by this one line rather than shared across them. Exposure to this line, rather than exposure to the market, is what determines a supplier's own rate.
- 02Regional weight, not regional count
North America is the largest region at USD 12.08 billion in 2025, 36.1% of global revenue, and reaches USD 20.42 billion by 2034 while holding 33.5%. Europe is next at 26.1% of revenue, USD 8.75 billion in 2025 and USD 14.93 billion in 2034. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03Fifteen years of unbroken growth underpin the forecast
Revenue rose through USD 22.8 billion in 2020, USD 31 billion in 2024 and USD 33.5 billion in 2025, a compound 8% across the historical period. From there the forecast carries 6.82% through to USD 60.95 billion in 2034. Because the growth is already in the record rather than in the projection, the rate is held flat across the forecast rather than ramped, and the risk in the number sits in the mix assumptions rather than in whether the market grows at all.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising chronic and infectious disease testing volume | High | +9.2 | High | High | Medium |
| 2 | Laboratory automation and platform consolidation | High | +7.1 | Medium | High | High |
| 3 | Expansion of companion diagnostics and oncology monitoring | Medium-High | +5.4 | Medium | Medium | High |
| 4 | Growth of point-of-care and decentralized testing | Medium-High | +4.1 | High | Medium | Medium |
| 5 | Public health screening program expansion in emerging markets | Medium | +2.95 | Medium | Medium | Low |
| 6 | Others | Low | +1.7 | Low | Low | Low |
| Total | +30.45 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Reagent pricing pressure from group purchasing and tender-based procurement | Medium-High | −1.9 | Medium | High | High |
| 2 | Regulatory and reimbursement delays for new assay approvals | Medium | −1.1 | High | Medium | Low |
| Total | −3 | |||||
Drivers contribute 30.45 Billion and restraints remove 3 Billion, a net 27.45 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
The 6.82% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the product axis, and where regional growth is concentrated.
Restraining Factors
Downside case: USD 57.29 billion rather than USD 60.95 billion by 2034
Market Restraints
2- 01Downside case: USD 57.29 billion rather than USD 60.95 billion by 2034
Where the forecast could miss: tender-based procurement compresses reagent pricing further than the base case assumes, and platform automation upgrades in cost-constrained laboratories are delayed. That path reaches USD 57.29 billion by 2034 instead of USD 60.95 billion, off an unchanged USD 33.5 billion in 2025.
- 02ELISA Reagents & Kits grows below the market rate
ELISA Reagents & Kits carries 24% of 2025 revenue at USD 8.04 billion but compounds at 5.23% against 6.82% for the market, taking its share to 21% by 2034 even as revenue rises to USD 12.8 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Upside case: USD 64.61 billion by 2034
Market Opportunities
2- 01Upside case: USD 64.61 billion by 2034
Companion diagnostic mandates and laboratory automation upgrades roll out faster than the base case, and reagent pricing holds firmer under tighter analyzer-reagent lock-in. On that assumption the market reaches USD 64.61 billion by 2034 rather than USD 60.95 billion, from the same USD 33.5 billion in 2025.
- 02Software & Services share moves from 9% to 11%
Software & Services grows at 9.2% against 6.82% for the market, adding revenue from USD 3.02 billion in 2025 to USD 6.71 billion in 2034 and taking its share from 9% to 11%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in ELISA Reagents & Kits.
Market Challenges
Revenue is concentrated in ELISA Reagents & Kits
Market Challenges
2- 01Revenue is concentrated in ELISA Reagents & Kits
With 24% of 2025 revenue and 21% of 2034 revenue (USD 8.04 billion rising to USD 12.8 billion) ELISA Reagents & Kits is where the market's exposure sits. A market leaning this heavily on one product line concentrates its exposure there, and a shift in demand for that line moves the total more than any other single change on the axis.
- 02One country drives the leading region
North America is worth USD 12.08 billion in 2025 and USD 10.4 billion of that is the United States; 86.09% of the region, reaching USD 17.55 billion in 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
5 axesSegmentation runs along five axes: product, specimen, technology, application and end-use. Revenue does not add across them: each is a different cut of the same total.
Nine product lines are reported. Four of them take share over the forecast period and the rest give it up, though every line grows in absolute terms between 2025 and 2034.
By Product · 9 segments
By Product
- Largest ELISA Reagents & Kits · 24%
- Fastest Software & Services · 9.2%
- Moves most ELISA Reagents & Kits · -3 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Reagents & Kits | $2.68B | 8% | $4.27B | 7%-1 | 5.2% |
| ELISA Reagents & Kits | $8.04B | 24% | $12.80B | 21%-3 | 5.2% |
| Rapid Test Reagents & Kits | $6.03B | 18% | $12.80B | 21%+3 | 8.7% |
| ELISPOT Reagents & Kits | $1.68B | 5% | $3.23B | 5.3%+0.3 | 7.5% |
| Western Blot Reagents & Kits | $2.01B | 6% | $3.35B | 5.5%-0.5 | 5.8% |
| Other Reagents & Kits | $1.34B | 4% | $2.26B | 3.7%-0.3 | 5.9% |
| Open Ended Systems | $4.69B | 14% | $7.62B | 12.5%-1.5 | 5.5% |
| Closed Ended Systems | $4.02B | 12% | $7.92B | 13%+1 | 7.8% |
| Software & Services | $3.02B | 9% | $6.71B | 11%+2 | 9.2% |
2025 to 2034 revenue and share by line: ELISA Reagents & Kits USD 8.04 billion to USD 12.8 billion (24% in 2025), Rapid Test Reagents & Kits USD 6.03 billion to USD 12.8 billion (18% in 2025), Open Ended Systems USD 4.69 billion to USD 7.62 billion (14% in 2025), Closed Ended Systems USD 4.02 billion to USD 7.92 billion (12% in 2025), Software & Services USD 3.02 billion to USD 6.71 billion (9% in 2025), Reagents & Kits USD 2.68 billion to USD 4.27 billion (8% in 2025), Western Blot Reagents & Kits USD 2.01 billion to USD 3.35 billion (6% in 2025), ELISPOT Reagents & Kits USD 1.68 billion to USD 3.23 billion (5% in 2025), Other Reagents & Kits USD 1.34 billion to USD 2.26 billion (4% in 2025). ELISA Reagents & Kits Held the Dominant Share of the Product Segment in 2025 ELISA-based reagents and kits lead the product mix because clinical laboratories standardized around plate-based enzyme immunoassay workflows decades ago, and switching costs for validated protocols stay high. Software and services is growing fastest as laboratories connect analyzer fleets into networked middleware and pay for remote monitoring and compliance support rather than treating instrumentation as a one-time purchase. ELISA Reagents & Kits remains the largest line through 2034, so the axis changes in proportion rather than in order. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Specimen · 4 segments
Saliva Outpaces the Axis While Blood Holds the Largest Share
- Largest Blood · 68%
- Fastest Saliva · 10.3%
- Moves most Blood · -3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Blood | $22.78B | 68% | $39.62B | 65%-3 | 6.3% |
| Urine | $6.03B | 18% | $10.36B | 17%-1 | 6.2% |
| Saliva | $3.02B | 9% | $7.31B | 12%+3 | 10.3% |
| Other Specimens | $1.68B | 5% | $3.66B | 6%+1 | 9.1% |
Blood-based testing leads because serum and plasma remain the reference matrix most immunoassay platforms are validated against, and reimbursement pathways are built around venous draws. Saliva is growing fastest as point-of-care and at-home formats favor a noninvasive matrix that avoids phlebotomy, particularly for hormone panels and infectious disease screening conducted outside clinical settings. The order does not change: Blood is still largest in 2034, and what moves is how much it holds.
By Technology · 5 segments
Chemiluminescence Immunoassays (CLIA) Both Leads the Technology Axis and Grows Fastest on It
- Largest Chemiluminescence Immunoassays (CLIA) · 42%
- Fastest Chemiluminescence Immunoassays (CLIA) · 8%
- Moves most Chemiluminescence Immunoassays (CLIA) · +4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Radioimmunoassay (RIA) | $2.01B | 6% | $2.44B | 4%-2 | 2.2% |
| Enzyme Immunoassays (EIA)Rapid Test | $10.05B | 30% | $16.46B | 27%-3 | 5.6% |
| Chemiluminescence Immunoassays (CLIA) | $14.07B | 42% | $28.04B | 46%+4 | 8% |
| Fluorescence Immunoassays (FIA) | $4.69B | 14% | $9.14B | 15%+1 | 7.7% |
| Others | $2.68B | 8% | $4.88B | 8% | 6.9% |
Chemiluminescence leads because it pairs the sensitivity laboratories need for low-abundance analytes with the automation and walk-away throughput large reference labs and hospital networks require. Radioimmunoassay is shrinking as its radioactive tracers carry disposal and licensing burdens that chemiluminescence and enzyme-based platforms do not, pushing replacement purchases toward automated, non-isotopic systems as instruments age out. Chemiluminescence Immunoassays (CLIA) remains the largest line through 2034, so the axis changes in proportion rather than in order.
By Application · 7 segments
By Application
- Largest Infectious Disease Testing · 32%
- Fastest Oncology · 8.9%
- Moves most Oncology · +3 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Therapeutic Drug Monitoring | $2.01B | 6% | $3.66B | 6% | 6.9% |
| Oncology | $5.36B | 16% | $11.58B | 19%+3 | 8.9% |
| Cardiology | $4.02B | 12% | $7.31B | 12% | 6.9% |
| Endocrinology | $6.70B | 20% | $10.97B | 18%-2 | 5.6% |
| Infectious Disease Testing | $10.72B | 32% | $18.29B | 30%-2 | 6.1% |
| Autoimmune Diseases | $3.35B | 10% | $6.70B | 11%+1 | 8% |
| Others | $1.34B | 4% | $2.44B | 4% | 6.9% |
2025 to 2034 revenue and share by line: Infectious Disease Testing USD 10.72 billion to USD 18.29 billion (32% to 30%), Endocrinology USD 6.7 billion to USD 10.97 billion (20% to 18%), Oncology USD 5.36 billion to USD 11.58 billion (16% to 19%), Cardiology USD 4.02 billion to USD 7.31 billion (12% to 12%), Autoimmune Diseases USD 3.35 billion to USD 6.7 billion (10% to 11%), Therapeutic Drug Monitoring USD 2.01 billion to USD 3.66 billion (6% to 6%), Others USD 1.34 billion to USD 2.44 billion (4% to 4%). Infectious Disease Testing Held the Dominant Share of the Application Segment in 2025 Infectious disease testing leads because it spans the broadest population, from prenatal and blood-donor screening to outbreak response, and immunoassay remains the fastest confirmatory format available at scale. Oncology is growing fastest as tumor marker monitoring and companion diagnostic testing expand alongside new targeted therapies, pulling immunoassay volume into treatment monitoring rather than diagnosis alone. By 2034 Infectious Disease Testing is still ahead, making this a shift in weight rather than a change of leader.
By End-use · 6 segments
Clinical Laboratories Led by End-use in 2025, with Pharmaceutical and Biotech Companies Growing Fastest
- Largest Clinical Laboratories · 36%
- Fastest Pharmaceutical and Biotech Companies · 8.9%
- Moves most Pharmaceutical and Biotech Companies · +3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospitals | $9.38B | 28% | $15.85B | 26%-2 | 6% |
| Blood Banks | $3.35B | 10% | $5.49B | 9%-1 | 5.6% |
| Clinical Laboratories | $12.06B | 36% | $21.33B | 35%-1 | 6.5% |
| Pharmaceutical and Biotech Companies | $5.36B | 16% | $11.58B | 19%+3 | 8.9% |
| Academic Research Centers | $2.01B | 6% | $4.27B | 7%+1 | 8.7% |
| Others | $1.34B | 4% | $2.44B | 4% | 6.9% |
Clinical laboratories lead because they consolidate testing volume from hospitals, physician offices and reference networks onto shared automated platforms, giving them the scale to negotiate reagent contracts. Pharmaceutical and biotech companies are growing fastest as drug developers embed immunoassay testing into clinical trials and companion diagnostic programs, a use case that barely existed at this scale a decade ago. Clinical Laboratories remains the largest line through 2034, so the axis changes in proportion rather than in order.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 2.6 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 1 of 5
- 2025 share 36.1%
- By 2034 33.5%
- Revenue $12.08B → $20.42B
North America holds 36.1% of the global immunoassay market in 2025, worth USD 12.08 billion rising to USD 20.42 billion in 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.
Share settles at 33.5% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Segment composition follows the global pattern: ELISA Reagents & Kits largest at 24% of 2025 revenue, Software & Services fastest at 9.2%. North America is reported axis by axis and country by country in the full study.
United States
Sets the pace for North America at 86.1% of it, growing 1.7×.
- In region 1 of 2
- Of region 86.1%
- Of global 31%
- Revenue $10.40B → $17.55B
USD 10.4 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 17.55 billion by 2034. Carrying 86.09% of the region in the base year, it sets North America's direction rather than contributing to it. Against regional totals of USD 12.08 billion in 2025 and USD 20.42 billion in 2034, it is the country the full report breaks out in detail.
The product pattern in the United States is the global one: 24% of 2025 revenue in ELISA Reagents & Kits, 21% by 2034, against 9.2% growth in Software & Services taking it from 9% to 11%. Since 86.09% of North America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Revenue by product for the United States is reported separately in the full report.
In the United States, immunoassay products are regulated as in vitro diagnostic devices under the Federal Food, Drug, and Cosmetic Act, placing them under the oversight of the Food and Drug Administration. Depending on the risk classification assigned to a given assay, a manufacturer must pursue either premarket notification or premarket approval before the product can be marketed, alongside adherence to the Quality System Regulation governing manufacturing controls. Clinical laboratories that run these assays are separately subject to Clinical Laboratory Improvement Amendments oversight, which sets requirements for laboratory certification and testing complexity categorization. Labelling must clearly state intended use, performance characteristics, and handling instructions to support accurate clinical interpretation by end users.
Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc. and Randox Laboratories Ltd are the suppliers covered in the United States. The commercially relevant division is 24% of 2025 revenue in ELISA Reagents & Kits, where the volume is, against 9.2% growth in Software & Services, where share moves. Country-level positioning and shares for each of these companies are part of the full report rather than this summary.
Canada
2nd-largest in North America, growing 1.7×.
- In region 2 of 2
- Of region 10.8%
- Of global 3.9%
- Revenue $1.30B → $2.15B
Canada is sized at USD 1.3 billion in 2025, rising to USD 2.15 billion by 2034; 3.88% of global revenue and 10.76% of North America. It is reported separately from the United States across every segmentation axis in the full report.
Europe Market Analysis
The 2nd-largest region covered — 1.6 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 2 of 5
- 2025 share 26.1%
- By 2034 24.5%
- Revenue $8.75B → $14.93B
26.1% of the global immunoassay market sits in Europe in 2025, worth USD 8.75 billion rising to USD 14.93 billion in 2034. That makes it the second-largest region covered, in 2025 and again in 2034.
Share settles at 24.5% in 2034, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
The product mix reported at global level applies here, with ELISA Reagents & Kits the largest line at 24% of 2025 revenue and Software & Services the fastest-growing at 9.2%. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 1.6×.
- In region 1 of 3
- Of region 26.9%
- Of global 7%
- Revenue $2.35B → $3.85B
Germany is the largest market within Europe, generating USD 2.35 billion in 2025 and projected to reach USD 3.85 billion by 2034. Its 26.86% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Regional revenue of USD 8.75 billion in 2025 and USD 14.93 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
The product pattern in Germany is the global one: 24% of 2025 revenue in ELISA Reagents & Kits, 21% by 2034, against 9.2% growth in Software & Services taking it from 9% to 11%. Its 26.86% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by product separately.
In Germany, immunoassay diagnostics fall under the European Union's In Vitro Diagnostic Regulation, which is enforced domestically through the Federal Institute for Drugs and Medical Devices. Manufacturers must classify their assays according to risk-based rules set out in the regulation, with higher-risk categories requiring conformity assessment by a notified body before a CE mark can be affixed. Suppliers must maintain a quality management system aligned with recognized international standards, compile technical documentation demonstrating performance and safety, and register devices and economic operators within the European database on medical devices. Labelling and instructions for use must be provided in German and include unique device identification.
The suppliers tracked in this study (Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc. and Randox Laboratories Ltd) compete in Germany across the product lines above. ELISA Reagents & Kits, at 24% of 2025 revenue, is where the volume sits, and Software & Services, growing at 9.2%, is where position changes hands over the forecast period.
United Kingdom
2nd-largest in Europe, growing 1.6×.
- In region 2 of 3
- Of region 21.1%
- Of global 5.5%
- Revenue $1.85B → $3.05B
The United Kingdom is sized at USD 1.85 billion in 2025, rising to USD 3.05 billion by 2034; 5.52% of global revenue and 21.14% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
France
3rd-largest in Europe, growing 1.6×.
- In region 3 of 3
- Of region 16%
- Of global 4.2%
- Revenue $1.40B → $2.30B
Within Europe, France accounts for 16% of regional revenue and 4.18% of the global total, worth USD 1.4 billion in 2025 and USD 2.3 billion by 2034.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 4.2 points of share by 2034, while revenue still grows 2.1×.
- Rank 3 of 5
- 2025 share 25.3%
- By 2034 29.5%
- Revenue $8.48B → $17.98B
In Asia Pacific, 25.3% of global revenue puts 2025 at USD 8.48 billion on the way to USD 17.98 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.
29.5% of global revenue sits here by 2034, up from the 2025 level, on growth above the market's own 6.82%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Within the region the product split tracks the global one; 24% of 2025 revenue in ELISA Reagents & Kits, fastest growth of 9.2% in Software & Services. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 2.3×.
- In region 1 of 3
- Of region 36.6%
- Of global 9.3%
- Revenue $3.10B → $7.05B
China is the largest market within Asia Pacific, generating USD 3.1 billion in 2025 and projected to reach USD 7.05 billion by 2034. 36.56% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 8.48 billion to USD 17.98 billion over the same period, and this is the market carrying the country-level detail in the full report.
China buys along the same lines as the market globally; ELISA Reagents & Kits first at 24% of 2025 revenue and 21% in 2034, Software & Services fastest at 9.2% on a share moving from 9% to 11%. Its 36.56% weight in Asia Pacific means those movements carry straight into the regional totals. The full report reports China by product separately.
In China, immunoassay reagents and instruments are regulated as in vitro diagnostic devices by the National Medical Products Administration. Products are classified according to risk, with lower-risk assays subject to a filing procedure and higher-risk assays requiring formal registration supported by clinical evaluation data generated domestically or accepted from recognized overseas trials. Manufacturers must operate under a quality management system consistent with national good manufacturing practice requirements and secure a registration certificate before commercial distribution. Imported products additionally require designation of a local agent responsible for regulatory liaison and post-market surveillance. Labelling, instructions for use, and packaging must be presented in Chinese and specify intended use and storage conditions.
Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc. and Randox Laboratories Ltd are the suppliers covered in China. ELISA Reagents & Kits, at 24% of 2025 revenue, is where the volume sits, and Software & Services, growing at 9.2%, is where position changes hands over the forecast period.
Japan
2nd-largest in Asia Pacific, growing 1.7×.
- In region 2 of 3
- Of region 24.8%
- Of global 6.3%
- Revenue $2.10B → $3.55B
6.27% of global revenue is generated in Japan; USD 2.1 billion in 2025, reaching USD 3.55 billion in 2034, and 24.76% of Asia Pacific.
India
3rd-largest in Asia Pacific, growing 2.4×.
- In region 3 of 3
- Of region 12.4%
- Of global 3.1%
- Revenue $1.05B → $2.55B
Within Asia Pacific, India accounts for 12.38% of regional revenue and 3.13% of the global total, worth USD 1.05 billion in 2025 and USD 2.55 billion by 2034.
Latin America Market Analysis
The 4th-largest region covered — it picks up 0.2 points of share by 2034, while revenue still grows 1.9×.
- Rank 4 of 5
- 2025 share 6.6%
- By 2034 6.8%
- Revenue $2.21B → $4.15B
USD 2.21 billion of 2025 revenue is generated in Latin America, 6.6% of the global immunoassay market rising to USD 4.15 billion in 2034. Among the five regions it ranks fourth by revenue in both years.
Share climbs to 6.8% by 2034, because it outgrows the market's 6.82%; the revenue added here is disproportionate to where the region started.
Segment composition follows the global pattern: ELISA Reagents & Kits largest at 24% of 2025 revenue, Software & Services fastest at 9.2%. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.
Brazil
The largest market in Latin America, growing 1.8×.
- In region 1 of 2
- Of region 47.5%
- Of global 3.1%
- Revenue $1.05B → $1.92B
USD 1.05 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 1.92 billion by 2034. Its 47.51% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Set against USD 2.21 billion and USD 4.15 billion for the region, it is why this market rather than a smaller one is the one reported in full.
The product pattern in Brazil is the global one: 24% of 2025 revenue in ELISA Reagents & Kits, 21% by 2034, against 9.2% growth in Software & Services taking it from 9% to 11%. With 47.51% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Brazil carries its own product breakdown in the full report.
In Brazil, immunoassay devices are regulated by the National Health Surveillance Agency, known locally as ANVISA, which oversees in vitro diagnostic products under its medical device framework. Manufacturers and importers must obtain product registration or, for lower-risk categories, complete a simplified notification, with the applicable route determined by the assay's risk classification. Facilities are expected to demonstrate compliance with Good Manufacturing Practice requirements, verified through inspection for higher-risk categories. Technical dossiers must document analytical performance, intended use, and safety data. Labelling, package inserts, and instructions for use must be presented in Portuguese, and products must remain traceable throughout distribution to support post-market vigilance obligations.
The suppliers tracked in this study (Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc. and Randox Laboratories Ltd) compete in Brazil across the product lines above. ELISA Reagents & Kits, at 24% of 2025 revenue, is where the volume sits, and Software & Services, growing at 9.2%, is where position changes hands over the forecast period.
Mexico
2nd-largest in Latin America, growing 1.9×.
- In region 2 of 2
- Of region 28.1%
- Of global 1.9%
- Revenue $0.62B → $1.18B
Within Latin America, Mexico accounts for 28.05% of regional revenue and 1.85% of the global total, worth USD 0.62 billion in 2025 and USD 1.18 billion by 2034.
Middle East and Africa Market Analysis
The 5th-largest region covered — 0.2 points of share move elsewhere by 2034, while revenue still grows 1.8×.
- Rank 5 of 5
- 2025 share 5.9%
- By 2034 5.7%
- Revenue $1.97B → $3.47B
USD 1.97 billion of 2025 revenue is generated in Middle East and Africa, 5.9% of the global immunoassay market with USD 3.47 billion projected for 2034. Among the five regions it ranks fifth by revenue in both years.
Its share moves to 5.7% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
ELISA Reagents & Kits leads here as it does globally, at 24% of 2025 revenue, and Software & Services again grows fastest at 9.2%. Middle East and Africa is reported axis by axis and country by country in the full study.
Saudi Arabia
The largest market in Middle East and Africa, growing 1.8×.
- In region 1 of 2
- Of region 29.4%
- Of global 1.7%
- Revenue $0.58B → $1.02B
29.44% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.58 billion, rising to USD 1.02 billion by 2034. At 29.44% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Against regional totals of USD 1.97 billion in 2025 and USD 3.47 billion in 2034, it is the country the full report breaks out in detail.
The product pattern in Saudi Arabia is the global one: 24% of 2025 revenue in ELISA Reagents & Kits, 21% by 2034, against 9.2% growth in Software & Services taking it from 9% to 11%. Because the country carries 29.44% of Middle East and Africa, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports Saudi Arabia by product separately.
In Saudi Arabia, immunoassay products are regulated by the Saudi Food and Drug Authority under its medical device framework, which governs in vitro diagnostics through the national Medical Devices Interim Regulation. Manufacturers and local authorized representatives must register devices through the Saudi Authorization system before marketing, with the classification and depth of technical review determined by the assay's risk category. Conformity to recognized international quality and safety standards is expected, along with maintenance of a quality management system and post-market surveillance capability. Labelling and instructions for use must be provided in Arabic alongside English, clearly identifying intended use, handling requirements, and the responsible local representative.
In Saudi Arabia the field is Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc. and Randox Laboratories Ltd. The commercially relevant division is 24% of 2025 revenue in ELISA Reagents & Kits, where the volume is, against 9.2% growth in Software & Services, where share moves.
South Africa
2nd-largest in Middle East and Africa, growing 1.7×.
- In region 2 of 2
- Of region 20.3%
- Of global 1.2%
- Revenue $0.40B → $0.68B
Within Middle East and Africa, South Africa accounts for 20.3% of regional revenue and 1.19% of the global total, worth USD 0.4 billion in 2025 and USD 0.68 billion by 2034.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by product, specimen, technology, application, end-use, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Position on the Product Axis Decides Competitive Standing
Suppliers in scope: Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc. and Randox Laboratories Ltd.
The competitive line that matters is the product one, not the geographic one. Volume sits in ELISA Reagents & Kits, USD 8.04 billion and 24% of 2025 revenue, 21% by 2034, which is also where an incumbent is hardest to dislodge. Software & Services, compounding at 9.2% against 5.23% for ELISA Reagents & Kits, is where share changes hands over the forecast period. A supplier positioned in one is not automatically positioned in the other, which is what keeps a field of this size viable in a market of USD 33.5 billion.
Competitive position in immunoassay rests on installed analyzer base and the reagent-lock that comes with it: once a laboratory validates a testing menu on a closed platform, switching cost keeps it buying that supplier's cartridges for years, which is why the largest diagnostics manufacturers compete on menu breadth and platform automation rather than price alone. Regulatory and clearance experience across multiple jurisdictions is a second real advantage, favoring companies with established submission pathways over new entrants. Smaller and regional suppliers compete on specialty assay depth, faster local regulatory registration, and direct distribution relationships in markets the largest players serve through partners.
Geographic reach is the other axis of competition. North America alone accounts for 36.1% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Europe adds a further 26.1%.
Profiles, financials, shares and development histories for each company sit in the full report; this summary carries the structure only.
List of Key Immunoassay Market Companies Profiled
15 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Siemens Healthineers(Germany)
- bioMérieux SA(France)
- Abbott Laboratories(United States)
- Danaher Corporation (Beckman Coulter)(United States)
- Quidel Corporation(United States)
- Ortho Clinical Diagnostics(United States)
- Sysmex Corporation(Japan)
- Bio-Rad Laboratories, Inc.(United States)
- Becton, Dickinson and Company(United States)
- F. Hoffmann-La Roche AG(Switzerland)
- Thermo Fisher Scientific, Inc.(United States)
- DiaSorin S.p.A.(Italy)
- Tosoh Corporation(Japan)
- PerkinElmer, Inc.(United States)
- Randox Laboratories Ltd(United Kingdom)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Product, Specimen, Technology, Application, End-use), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 15 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Immunoassay Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Immunoassay Market Overview, By Product, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Immunoassay Market Overview, By Specimen, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Immunoassay Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Immunoassay Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Immunoassay Market Overview, By End-use, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Immunoassay Market Size — Segment Comparison
Chapter 22.Global Immunoassay Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Immunoassay Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Immunoassay Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Immunoassay Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Immunoassay Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Immunoassay Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Product
9- 01Reagents & Kits
- 02ELISA Reagents & Kits
- 03Rapid Test Reagents & Kits
- 04ELISPOT Reagents & Kits
- 05Western Blot Reagents & Kits
- 06Other Reagents & Kits
- 07Open Ended Systems
- 08Closed Ended Systems
- 09Software & Services
By Specimen
4- 01Blood
- 02Urine
- 03Saliva
- 04Other Specimens
By Technology
5- 01Radioimmunoassay (RIA)
- 02Enzyme Immunoassays (EIA)Rapid Test
- 03Chemiluminescence Immunoassays (CLIA)
- 04Fluorescence Immunoassays (FIA)
- 05Others
By Application
7- 01Therapeutic Drug Monitoring
- 02Oncology
- 03Cardiology
- 04Endocrinology
- 05Infectious Disease Testing
- 06Autoimmune Diseases
- 07Others
By End-use
6- 01Hospitals
- 02Blood Banks
- 03Clinical Laboratories
- 04Pharmaceutical and Biotech Companies
- 05Academic Research Centers
- 06Others
Segment categories shown for scope reference. See the Summary tab for revenue share by By Product. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
This market was built upward from immunoassay test volumes: the number of assay runs performed across chemiluminescence, ELISA, rapid-test and other platform types by region, multiplied by the realized reagent price per run and the analyzer placement base that supports that run rate. Instrument revenue was built separately from unit placements and typical service-contract pricing, then added to reagent revenue. This bottom-up build was checked against the disclosed diagnostics segment revenue reported by the major immunoassay manufacturers named in this report, and against the reagent-to-instrument revenue ratios those companies disclose. Where the bottom-up volume estimate implied a run-rate inconsistent with a company's own disclosed segment revenue, the volume or price assumption was corrected rather than averaging the two figures together.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews targeted laboratory directors and procurement managers at hospital and reference laboratories who set testing-menu and platform decisions, commercial and marketing leads at diagnostics manufacturers who set reagent pricing and channel strategy, and regulatory affairs staff who track clearance timelines for new assays in each jurisdiction. Distribution partners in markets served through third parties were also sampled to understand list-to-net pricing gaps that manufacturer disclosures do not show directly. Sampling emphasized the United States, Germany and China, the three markets where testing volume and platform density are highest, with lighter coverage across smaller Latin American and Middle Eastern markets where laboratory consolidation is less advanced and fewer procurement decision-makers cover a comparable volume of testing.
Desk research drew on the FDA's 510(k) and PMA clearance databases for assay approvals, the CE marking and IVDR registration records maintained under EU medical device regulation, and China's NMPA registration filings, each of which records the specific analyte and platform an assay is cleared for. Customs trade data under HS code 3822 (diagnostic and laboratory reagents) was used to cross-check regional shipment patterns against reported revenue. Publicly disclosed segment revenue and investor-day disclosures from the manufacturers named in this report, along with CLSI and WHO prequalification guidance documents that describe testing protocols by region, rounded out the source base.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast carries forward regional testing-volume growth tied to chronic and infectious disease prevalence trends, laboratory automation adoption curves in markets still running manual or semi-automated platforms, and the pace at which companion diagnostic requirements are written into new drug approvals. Reagent pricing is held roughly flat in real terms in mature markets and modeled as gradually converging toward those levels in markets where tender-based procurement is still compressing prices. The COVID-era testing volume spike embedded in 2020-2021 volumes was normalized out of the base before projecting forward, since it does not represent a recurring demand pattern. The forecast holds if disease-testing volumes continue their pre-pandemic trend rather than reverting further.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs were back-tested against each region's recorded 2020-2024 testing-volume and revenue growth to confirm the forecast slope does not diverge sharply from realized history without a stated reason. Segment share shifts, including the move toward chemiluminescence platforms and away from radioimmunoassay, were reviewed against the same manufacturers' own disclosed product-mix commentary to confirm direction and rough pace. Sensitivities were tested on reagent price assumptions and on the pace of platform automation adoption in laboratories still running manual workflows, since those two inputs move the forecast more than any regional GDP or demographic assumption tested alongside them.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmest in the United States, Germany and Japan, where disclosed manufacturer segment revenue and regulatory filings both exist and largely agree. It is weaker in Latin America and parts of the Middle East and Africa, where laboratory testing volume is reported inconsistently and reagent pricing is triangulated from distributor pricing rather than direct disclosure. Rapid-test and point-of-care segments carry more uncertainty than laboratory-platform segments because informal and unregistered testing volume in some markets is not captured in any of the sources used here. A material shift in reimbursement policy for companion diagnostics would be the clearest trigger for revision.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Immunoassay Market projected to reach?
USD 60.95 Billion by 2034, CAGR 6.82%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 36.1% of global revenue through 2034.
05Which segment leads the market?
ELISA Reagents & Kits is the largest line by product, at 24% of revenue in 2025.
06Who are the key companies profiled?
Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc., Randox Laboratories Ltd. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.